BetterLife Pharma

BetterLife Pharma Inc (CSE:BETR, OTCQB:BETRF) said that one of its scientific collaborators, Dr Argel Aguilar-Valles from Carleton University's Department of Neuroscience, will make a presentation on the anti-depressant activity of the company's lead compound, its proprietary 2-bromo-LSD (BETR-001), at the four-day American College of Neuropsychopharmacology (ACNP) annual conference in Phoenix, Arizona starting on December 4, 2022.  The Vancouver, British Columbia-based biotech's BETR-001 is a non-hallucinogenic Lysergic Acid Diethylamide (LSD) derivative molecule. » Mehr auf proactiveinvestors.com

VANCOUVER, British Columbia, Dec. 02, 2022 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, today announced that one of its scientific collaborators, Dr. Argel Aguilar-Valles from Carleton University's Department of Neuroscience (Ottawa, Canada), will present on the anti-depressant activity of 2-bromo-LSD (“BETR-001”), the Company's lead compound, at the upcoming ACNP Conference being held December 4 to 7 at Phoenix, Arizona, USA. BETR-001 is a non-hallucinogenic Lysergic Acid Diethylamide (“LSD”) derivative molecule.Dr. Aguilar-Valles will present preclinical data supporting the acute and long-term anti-depressant activity of BETR-001 monotherapy in animal models. Furthermore, the data shows that BETR-001 promotes structural neuroplasticity in brain neurons and this effect is partly mediated by the activation of 5-HT2A receptor.Dr. Ahmad Doroudian, CEO of BetterLife commented, “BETR-001 is a uniquely positioned LSD derivative with the potential to be as effective as LSD in various neuropsychiatric and neurological disorders without the burden of being hallucinogenic. Because of its non-hallucinogenic nature, BETR-001 will not have all the LSD requirements of administration in specialized clinics under special treatment protocols, the LSD controlled substance regulatory issues which impact manufacturing, distribution and patient access, and the overall associated high treatment costs for all these parameters. Additionally, BETR-001 is protected by BetterLife's composition, method-of-use, synthesis and formulation patents (issued and provisional).” He further added, “BETR-001 IND-enabling studies are being completed and we hope to file its IND and begin human trials by mid-2023.” » Mehr auf globenewswire.com

BetterLife Pharma Inc (CSE:BETR, OTCQB:BETRF) said it has filed a PCT patent application along with a US application for lysergic acid diethylamide (LSD) derivatives, including 2-bromo-LSD. The applications cover compositions of these derivatives for use in the treatment of a range of neuropsychiatric and neurological conditions, including depression, anxiety, cluster headaches and pain, according to BetterLife. » Mehr auf proactiveinvestors.com